In this webinar, Dr. Carneiro will introduce her team's work on optimizing lipid nanoparticles (LNPs) to enhance the delivery and effectiveness of CRISPR/Cas9 for targeting KRAS mutations in lung tumors. She will guide us through the process of LNP formulation optimization, including formulation screening, physicochemical characterization, and rigorous in vitro and in vivo safety and efficacy assessments.
